# Iota Biosciences

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/iota-biosciences
Canonical HTML page: https://getbiobrief.com/entity/iota-biosciences

## Timeline

- **2026-Q3**: Bioelectronic Medicine Forum — The forum convenes in NYC to discuss the future of neural interfaces.
- **2026-03-05**: Keynote Announcement — Jose Carmena announced as keynote for the 2026 Bioelectronic Medicine Forum in NYC.
- **2026-03-05**: Keynote Announcement — Iota Biosciences founder announced as the lead speaker for the NYC Forum.
- **2020-10-15**: Astellas Acquisition — Astellas Pharma acquires Iota Biosciences to bolster its 'Rx+' innovation strategy.
- **2020-10-15**: Astellas Acquisition — Astellas Pharma acquires Iota Biosciences to bolster its Rx+ electronics division.
- **2017-05-01**: Iota Biosciences Founded — Jose Carmena and Michel Maharbiz spin out 'neural dust' technology from UC Berkeley.

## Recent coverage (2 stories)

### Iota Biosciences Founder to Keynote 2026 Bioelectronic Medicine Forum
2026-03-06 00:23:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 7

The founder of Iota Biosciences will headline the 2026 Bioelectronic Medicine Forum in New York, marking a pivotal moment for the neurotechnology sector. The event will feature a global cohort of innovators, including European firms Coherence Neuro and Graphenicalab, alongside U.S. startup Spiro Medical.
Full story: https://getbiobrief.com/story/iota-biosciences-keynote-2026-bioelectronic-forum

### Iota Biosciences Founder to Keynote 2026 Bioelectronic Medicine Forum in NYC
2026-03-05 14:19:12 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Jose Carmena, co-founder of Iota Biosciences, has been named the keynote speaker for the 2026 Bioelectronic Medicine Forum in New York City. The event highlights the accelerating shift toward ultrasound-powered 'neural dust' and minimally invasive neuromodulation therapies.
Full story: https://getbiobrief.com/story/iota-biosciences-founder-keynote-2026-bioelectronic-medicine-forum

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.